Enara Bio is a oncology focused biotechnology company located in Oxford, United Kingdom committed to discovering and progressing novel cancer immunotherapies for solid tumor lines.
Enara Bio Funding
- Amount Raised: $32.5M in Series B funding
- Key Investors:
- Led by Pfizer Ventures and M Ventures
- Participation from existing investors: RA Capital, Samsara BioCapital, SV Health Investors
- New Investor: The Francis Crick Institute
- Purpose of Funding: To advance the pipeline of TCR-based immunotherapies targeting Dark Antigen targets for cancer treatment.
Enara Bio’s Platform - EDAPT
- EDAPT Platform: Utilizes cutting-edge bioinformatics, immunopeptidomics, and RNA in situ hybridization to discover and validate Dark Antigen targets.
- Target: Dark Antigens, cancer-specific antigens expressed on solid tumor cells.
- Focus: Development of TCR-based immunotherapies with cancer specificity and potential to combat solid tumors effectively.
Enara Bio Careers
Enara Bio offers exciting career opportunities for professionals passionate about biotechnology and cancer immunotherapy. For details on Enara Bio jobs, visit their website or check career portals for the latest job openings.
With its expanding pipeline and strong investor backing, Enara Bio continues to grow, creating more opportunities in biotechnology, research, and innovation.
**To get all UK Startup news Please Visit – https://growwseed.com/category/uk-startup-funding-news/
